TABLE 3.
Antibody concentrations and OPA titers in selected sera from Finnish children vaccinated with 7vCRM, 7vOMPC, or 11Pn-PD at the ages of 2, 4, 6, and 12 to 15 monthsa
| Vaccine (n)b | 22F-ELISA |
OPA assay |
||||||
|---|---|---|---|---|---|---|---|---|
| % of samples with antibody concns of ≥0.35 μg/ml (95% CI) |
GMC (μg/ml) (95% CI) |
% of samples with OPA titers of ≥8 (95% CI) |
OPA GMT (95% CI) |
|||||
| 19F | 19A | 19F | 19A | 19F | 19A | 19F | 19A | |
| 7vCRM (29-30) | 100 (88-100) | 72 (53-87) | 9.3 (7.2-11.9) | 0.7 (0.5-1.0) | 100 (88-100) | 10 (2-27) | 55.7 (39.9-77.8) | 4.9 (3.8-6.3) |
| 7vOMPC (29-30) | 100 (88-100) | 62 (42-79) | 9.3 (7.5-11.6) | 0.4 (0.3-0.6) | 87 (69-96) | 20 (8-39) | 35 (22-55) | 4.9 (4.2-5.8) |
| 11Pn-PD (25-26) | 100 (86-100) | 44 (24-65) | 11.9 (8.8-16.0) | 0.4 (0.3-0.7) | 100 (86-100) | 68 (47-85) | 99.6 (74.6-133.3) | 14.6 (9.0-24.1) |
a
Samples were obtained from children 1 month after the third or the fourth PCV dose, with a 2:1 ratio between the number of samples taken after three and four doses. GMC, geometric mean concentration; GMT, geometric mean titer.
b
n, number of serum samples for which results were available.